Holen Sie sich die Stockscreener-App
75.60
1.60%
1.19
Schlusskurs vom Vortag:
$74.41
Offen:
$75
24-Stunden-Volumen:
1.34M
Relative Volume:
0.87
Marktkapitalisierung:
$10.15B
Einnahmen:
$3.10B
Nettoeinkommen (Verlust:
$586.71M
KGV:
17.61
EPS:
4.2937
Netto-Cashflow:
$605.57M
1W Leistung:
+1.45%
1M Leistung:
-6.27%
6M Leistung:
-14.01%
1J Leistung:
+30.21%
1-Tages-Spanne:
$74.22
$76.16
1-Wochen-Bereich:
$73.67
$76.16
52-Wochen-Spanne:
$56.50
$101.40
Globus Medical Inc Stock (GMED) Company Profile
Firmenname
Globus Medical Inc
Sektor
Branche
Telefon
610-930-1800
Adresse
2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA
Compare GMED vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GMED
Globus Medical Inc
|
75.60 | 10.01B | 3.10B | 586.71M | 605.57M | 4.2937 |
ABT
Abbott Laboratories
|
97.50 | 168.71B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.38 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.43 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
42.60 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.15 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Globus Medical Inc Stock (GMED) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-07-28 | Eingeleitet | UBS | Neutral |
| 2026-07-09 | Eingeleitet | BMO Capital Markets | Outperform |
| 2026-01-30 | Hochstufung | Needham | Hold → Buy |
| 2026-01-27 | Eingeleitet | TD Cowen | Buy |
| 2025-11-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-11-07 | Hochstufung | Truist | Hold → Buy |
| 2025-10-28 | Fortgesetzt | Stifel | Hold |
| 2025-05-27 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-01-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-08-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-05-20 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-03-18 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-10-20 | Eingeleitet | ROTH MKM | Buy |
| 2023-09-19 | Hochstufung | Stifel | Hold → Buy |
| 2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-02-13 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-02-10 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-02-10 | Herabstufung | Loop Capital | Buy → Hold |
| 2023-02-10 | Herabstufung | Needham | Buy → Hold |
| 2023-02-10 | Herabstufung | Truist | Buy → Hold |
| 2023-02-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-04-13 | Fortgesetzt | Truist | Buy |
| 2022-03-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-01-04 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-12-13 | Hochstufung | BofA Securities | Underperform → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-29 | Eingeleitet | Loop Capital | Buy |
| 2021-02-18 | Fortgesetzt | Needham | Buy |
| 2020-12-08 | Eingeleitet | Citigroup | Buy |
| 2020-10-20 | Eingeleitet | Stifel | Hold |
| 2020-08-06 | Bestätigt | Needham | Buy |
| 2020-08-06 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-07-21 | Eingeleitet | Northland Capital | Market Perform |
| 2020-07-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-05-08 | Bestätigt | Needham | Buy |
| 2020-03-18 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-01-08 | Eingeleitet | SunTrust | Buy |
| 2019-12-12 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2019-08-02 | Bestätigt | Needham | Buy |
| 2019-05-24 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2019-05-03 | Bestätigt | Needham | Buy |
| 2019-02-28 | Hochstufung | UBS | Neutral → Buy |
| 2019-01-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-08-02 | Bestätigt | Needham | Buy |
| 2018-06-27 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-06-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-05-03 | Bestätigt | Needham | Buy |
| 2018-04-04 | Hochstufung | Needham | Hold → Buy |
Alle ansehen
Globus Medical Inc Aktie (GMED) Neueste Nachrichten
Neogen Stock Rallies 83% YTD: What's Driving the Surge? - Zacks Investment Research
RBC Cuts Price Target on Globus Medical to $85 From $115, Keeps Outperform Rating - marketscreener.com
Globus Medical, Inc. (GMED) Stock Forecasts - Yahoo Finance
GM0N Forecast — Price Target — Prediction for 2027 - TradingView
Basic earnings per share (basic EPS) of Globus Medical Inc Class A – HAN:GM0N - TradingView
Globus Medical (GMED) Pulls Back Following Recent Weakness, Is The Stock Trading At A Discount? - Yahoo Finance
2 Reasons to Watch GMED and 1 to Stay Cautious - Yahoo Finance
Globus Medical stock expands its European imaging opportunity - AD HOC NEWS
GM0N.MU interactive stock chart | Globus Medical Inc. R stock - Yahoo Finance Australia
Globus Medical, Inc. (GMED) Stock forecasts - Yahoo Finance UK
Q2 Earnings Highs And Lows: Globus Medical (NYSE:GMED) Vs The Rest Of The Medical Devices & SuppliesSpecialty Stocks - Yahoo Finance
'Moskowitz v. Globus Medical': The Federal Circuit Affirms That Claim Preambles Were Limiting, Sinking Patent Case - Law.com
Globus Medical Inc. (US3795772082.SG) - Yahoo! Finance Canada
What Marks a New Chapter for Globus Medical (NYSE:GMED) on NYSE? - Kalkine Media
Price performance - Yahoo Finance Australia
Prim prorroga el contrato de distribución con Globus Medical hasta 2033 - TradingView
Globus Medical Inc (GM0N.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Globus Medical, Inc. (GMED) Stock Analysis: Exploring a 39.35% Potential Upside Amid Robust Healthcare Innovations - DirectorsTalk Interviews
Wall Street Analysts Believe Globus Medical (GMED) Could Rally 25.03%: Here's is How to Trade - Eastern Progress
Globus Medical (GMED) Stock May Trade At A Discount On Earnings - Yahoo Finance
BTIG reiterates Globus Medical stock rating amid Nevro concerns By Investing.com - Investing.com Canada
Weave Announces Acquisition by Francisco Partners | Globus Medical Announces Acquisition of Higgs Boson Health - Healthcare IT Today
Tobin James R Executes 30,000 Globus Medical Options and Sells Shares at $74.58 Each - Kalkine Media
Globus Medical Director James R. Tobin Executes Stock Options and Sells 30,000 Shares on September 15, 2026 - Kalkine Media
Globus Medical Director Sold Shares Worth Over $2.2M - TradingView
Globus Medical (GMED) director sells shares not under preset trading plan - Stock Titan
What Makes Globus Medical (GMED) a New Strong Buy Stock - finance.yahoo.com
Globus Medical Q2 2026: Spine Drives Growth: Earnings Shift Into Higher Gear - Orthopedics This Week
Director at Globus Medical (NYSE: GMED) to sell 30,000 shares via option exercise - Stock Titan
Globus Medical, Inc. (GMED) Stock Analysis: Navigating a 39% Potential Upside in the Medical Devices Sector - DirectorsTalk Interviews
Fed. Circ. Agrees Globus Didn't Infringe Spinal Surgery IP - Law360
Globus Medical Maintains Spinal Surgery Patent Win on Appeal - Bloomberg Law News
Has Globus Medical (GMED) Fallen Far Enough To Be A Bargain? - webull.com
Audubon’s Globus Medical Brings Its 3-in-1 Surgical Imaging System to European Union - BioBuzz
Zacks Industry Outlook Highlights Veracyte, Globus Medical and UFP Technologies - Yahoo Finance
Zacks.com featured highlights include Globus Medical, NetApp and Assurant - Yahoo Finance
3 Medical Instruments Stocks Banking on GenAI to Tackle Industry Woes - TradingView
Globus Medical Inc (GMED) Shares Fall 4.2% -- What GF Score of 9 - GuruFocus
Globus Medical Clears Excelsius3D for European Sales - MyChesCo
Globus Medical, Inc. (GMED) Stock Analysis: Healthcare Innovator with a 31.86% Upside Potential - DirectorsTalk Interviews
Globus Medical (GMED) Received CE Mark For Its Excelsius3D Imaging System - Yahoo Finance
Globus Medical Announces CE Mark for Excelsius3D™ Imaging System Excelsius3D™ – Intelligent 3-in-1 Imaging System Expands Excelsius™ Ecosystem in the European Union - Orthopedics This Week
Globus Medical Announces CE Mark for Excelsius3D™ Imaging System - Ortho Spine News
Globus Medical’s Excelsius3D imaging system receives CE mark - Yahoo Finance
Finanzdaten der Globus Medical Inc-Aktie (GMED)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.26%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):